New MIT Nanotech Fights Cancer Naturally
September 20, 2010 8:30 AM
comment(s) - last by
Harnessing the body's own defense forces to fight cancer with nanoscale technology.
In the myriad advances in treating cancer, many a nanotech study has crossed
path. This week another such study was revealed by the journal
(abstract). In the past, we’ve seen all sorts of man-made nanoparticles both acting as a force of cell destruction and as a ferry, shipping anti-tumor drugs straight to cancer cells where they can be of the most benefit. This latest method by Massachusetts Institute of Technology researchers is akin to the latter, but instead of using nanoparticles to deliver drugs, they deliver modified immune cells from the patient’s own body.
Dr. Darrell Irvine, the team leader for the MIT study, spoke optimistically of the new treatment. “What we're looking for is the extra nudge that could take immune-cell therapy from working in a subset of people to working in nearly all patients, and to take us closer to cures of disease rather than slowing progression.”
The process by which the treatment is administered
. T cells, a type of white blood cell which is involved in cell-mediated immunity, are harvested from the patient’s blood. They are then treated in such a way so that they specifically target cancer cells. The new T cells are then attached to a lipid-based nanoparticle filled with interleukins. Interleukins are a type of chemical that helps promote the growth of T cells. Finally, the T cell and interleukin-laden nanoparticles are injected back into the patient, where the T cells seek out the tumors they’ve been programmed to destroy. The interleukins help maintain a healthy T cell count to combat the cancer cells directly without causing aberrant production elsewhere in the body.
The final part here is important. Interleukin treatments have already been widely tested in cancer patients to promote cancer-fighting T cell growth, but the treatments can have devastating side effects including heart and lung failure. The targeted approach used by Irvine’s group holds the runaway T cell production process in check by only allowing those at the tumor’s area to be affected.
In a trial using mice, the treatment was found to be 100% effective. While standard T cell or T cell and interleukin treatment mice died after 75 days, the control mice died after only 25 days and the mice given the nanoparticle treatment lived on past the 100 day limit of the study.
This article is over a month old, voting and posting comments is disabled
RE: Pretty crappy side effect...
9/20/2010 12:29:04 PM
The treatment this technology is attempting to REPLACE can have devastating side effects.
Did any of us say otherwise?
"It seems as though my state-funded math degree has failed me. Let the lashings commence." -- DailyTech Editor-in-Chief Kristopher Kubicki
Creationists are Mad About Google Doodle Depicting Evolution
November 24, 2015, 8:48 PM
DHS and TSA: Whoops, We Missed That 73 Airport Employees May be Terrorists
November 19, 2015, 2:16 PM
Star Wars Spinoff Film "Rogue One", Theme Park Attractions Announced
August 17, 2015, 12:20 PM
SpaceX Falcon 9's Seventh Supply Mission to ISS Ends w/ Fiery Stage 1 Explosion
June 28, 2015, 1:10 PM
Cool Science Video: Glowing Millipede Prowls the Nevada Desert
May 18, 2015, 12:00 PM
Newly Discovered Costa Rican Glass Frog is Kermit's Doppelgänger
April 22, 2015, 11:26 AM
Latest Blog Posts
Sceptre Airs 27", 120 Hz. 1080p Monitor/HDTV w/ 5 ms Response Time for $220
Dec 3, 2014, 10:32 PM
Costco Gives Employees Thanksgiving Off; Wal-Mart Leads "Black Thursday" Charge
Oct 29, 2014, 9:57 PM
"Bear Selfies" Fad Could Turn Deadly, Warn Nevada Wildlife Officials
Oct 28, 2014, 12:00 PM
The Surface Mini That Was Never Released Gets "Hands On" Treatment
Sep 26, 2014, 8:22 AM
ISIS Imposes Ban on Teaching Evolution in Iraq
Sep 17, 2014, 5:22 PM
More Blog Posts
Copyright 2016 DailyTech LLC. -
Terms, Conditions & Privacy Information